AMGN catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
November 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Nov 30, 2026Sponsor estimate | NCT05094336A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)Amgen · Advanced MTAP-null Solid Tumors | AMGNLead | Phase 1/Phase 2 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Nov 30, 2026Sponsor estimatePhase 1/Phase 2NCT05094336A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)Amgen · Advanced MTAP-null Solid TumorsActive, not recruitingAMGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
December 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Dec 2026Sponsor estimate | NCT07102394Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1Johns Hopkins University · NF1 | AMGNCollaborator | Phase 1 | Recruiting | Locked | Locked | Locked |
| Dec 17, 2026Sponsor estimate | NCT04185883Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)Amgen · Advanced Solid Tumors | AMGNLead | Phase 1 | Active, not recruiting | Locked | Locked | Locked |
| Dec 30, 2026Sponsor estimate | NCT03114865A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission MaintenanceSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Acute Lymphoblastic Leukemia | AMGNCollaborator | Phase 1/Phase 2 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Dec 2026Sponsor estimatePhase 1NCT07102394Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1Johns Hopkins University · NF1RecruitingAMGNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 17, 2026Sponsor estimatePhase 1NCT04185883Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)Amgen · Advanced Solid TumorsActive, not recruitingAMGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2026Sponsor estimatePhase 1/Phase 2NCT03114865A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission MaintenanceSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Acute Lymphoblastic LeukemiaActive, not recruitingAMGNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Jan 6, 2027Sponsor estimate | NCT06401044A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye DiseaseAmgen · Thyroid Eye Disease | AMGNLead | Phase 1/Phase 2 | Active, not recruiting | Locked | Locked | Locked |
| Jan 10, 2027Sponsor estimate | NCT07908641Comparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release...Amgen · Psoriasis | AMGNLead | Phase 1 | Not yet recruiting | Locked | Locked | Locked |
| Jan 14, 2027Sponsor estimate | NCT07811999Comparing the Extent to Which Romosozumab (AMG 785) is Made Available in the Body When Administered as a Single SC Injection or as 2 SC...Amgen · Healthy Participants | AMGNLead | Phase 1 | Recruiting | Locked | Locked | Locked |
- Primary completion Jan 6, 2027Sponsor estimatePhase 1/Phase 2NCT06401044A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye DiseaseAmgen · Thyroid Eye DiseaseActive, not recruitingAMGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 10, 2027Sponsor estimatePhase 1NCT07908641Comparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release...Amgen · PsoriasisNot yet recruitingAMGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 14, 2027Sponsor estimatePhase 1NCT07811999Comparing the Extent to Which Romosozumab (AMG 785) is Made Available in the Body When Administered as a Single SC Injection or as 2 SC...Amgen · Healthy ParticipantsRecruitingAMGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
February 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Feb 17, 2027Sponsor estimate | NCT06613100Evaluation of Neoadjuvant Xaluritamig in Localized Prostate CancerAmgen · Prostate Cancer | AMGNLead | Phase 1 | Recruiting | Locked | Locked | Locked |
- Primary completion Feb 17, 2027Sponsor estimatePhase 1NCT06613100Evaluation of Neoadjuvant Xaluritamig in Localized Prostate CancerAmgen · Prostate CancerRecruitingAMGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 8 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.